Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut

Shares of Ascletis Pharma, the first early-stage biotechnology company to list in Hong Kong under new rules, tumbled on Friday, their third day of trading.